Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclotron-produced vs Generator-produced Tc-99m Pertechnetate in Thyroid Disorders
NCT02980679Phase 3Completed
- Sponsor
- University of Alberta
- Start
- Mar 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of technetium Tc-99m sodium pertechnetate in thyroid disease, sponsored by University of Alberta. Primary endpoint: Clinical Comparability of CTC with G-PERT at 1 year. Started Mar 2017; status: completed.
02
Drugs
technetium Tc-99m sodium pertechnetate
03
Conditions
thyroid disease
Beyond the preview
Go deeper on NCT02980679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02980679.